{
  "component_scores": {
    "joint_involvement": {
      "score": 5,
      "justification": "Multiple joint mentions, including polyarthrite rhumatoïde and rheumatoid arthritis (confirmed)"
    },
    "serology": {
      "score": 0,
      "justification": "Negative RF and negative anti-CCP"
    },
    "acute_phase": {
      "score": 1,
      "justification": "CRP value is unknown, but patient has a high VHS (20 mm/h)"
    },
    "duration": {
      "score": 0,
      "justification": "No mention of chronic or long-standing condition"
    }
  },
  "acr_eular_total": 6,
  "treatment_context": {
    "has_dmard": false,
    "treatment_strength": "none",
    "justification": "No indication of DMARDs, biologic JAK inhibitors or other treatment mentioned in the facts."
  },
  "final_label": "RA−",
  "classification_rationale": "The patient has a high VHS (20 mm/h) which suggests an active inflammatory process. The presence of multiple joint involvement with rheumatoid arthritis is noted, but there are no positive serological markers and no DMARD treatment. Therefore, despite the clinical picture suggesting possible RA, the absence of strong evidence from serology or treatment does not meet the criteria for a definitive diagnosis.",
  "confidence": "medium",
  "patient_id": "0011",
  "agent": "Agent2_LLM_Reasoning_BALANCED",
  "retrieved_guidelines": [
    {
      "title": "Clinical Context",
      "content": "Treatment patterns provide additional evidence:\n- Methotrexate (MTX) = first-line csDMARD\n- Biologic DMARDs (anti-TNF, anti-IL6, etc.) = established RA\n- JAK inhibitors = treatment-refractory RA\n\nIn clinical practice:\n- Score ≥6/10 = definite RA\n- Score 4-5/10 + DMARD treatment = probable established RA\n- Score ≥5/10 without treatment = borderline, likely RA",
      "text": "Clinical Context Treatment patterns provide additional evidence:\n- Methotrexate (MTX) = first-line csDMARD\n- Biologic DMARDs (anti-TNF, anti-IL6, etc.) = established RA\n- JAK inhibitors = treatment-refractory RA\n\nIn clinical practice:\n- Score ≥6/10 = definite RA\n- Score 4-5/10 + DMARD treatment = probable established RA\n- Score ≥5/10 without treatment = borderline, likely RA",
      "relevance_score": 4.683000883810066
    },
    {
      "title": "Category B: Serology (0-3 points)",
      "content": "- Negative RF AND negative ACPA: 0 points\n- Low-positive RF OR low-positive ACPA (≤3× ULN): 2 points\n- High-positive RF OR high-positive ACPA (>3× ULN): 3 points\n\nRF = Rheumatoid Factor\nACPA = Anti-citrullinated protein antibody (anti-CCP)\nULN = Upper limit of normal (typically RF: 20 IU/mL, anti-CCP: 10 U/mL)",
      "text": "Category B: Serology (0-3 points) - Negative RF AND negative ACPA: 0 points\n- Low-positive RF OR low-positive ACPA (≤3× ULN): 2 points\n- High-positive RF OR high-positive ACPA (>3× ULN): 3 points\n\nRF = Rheumatoid Factor\nACPA = Anti-citrullinated protein antibody (anti-CCP)\nULN = Upper limit of normal (typically RF: 20 IU/mL, anti-CCP: 10 U/mL)",
      "relevance_score": 3.7519987234196357
    },
    {
      "title": "Category A: Joint Involvement (0-5 points)",
      "content": "- 1 large joint: 0 points\n- 2-10 large joints: 1 point\n- 1-3 small joints (with or without large joints): 2 points\n- 4-10 small joints (with or without large joints): 3 points\n- >10 joints (at least 1 small joint): 5 points\n\nLarge joints: shoulders, elbows, hips, knees, ankles\nSmall joints: MCPs, PIPs, MTPs (2nd-5th), thumb IPs, wrists",
      "text": "Category A: Joint Involvement (0-5 points) - 1 large joint: 0 points\n- 2-10 large joints: 1 point\n- 1-3 small joints (with or without large joints): 2 points\n- 4-10 small joints (with or without large joints): 3 points\n- >10 joints (at least 1 small joint): 5 points\n\nLarge joints: shoulders, elbows, hips, knees, ankles\nSmall joints: MCPs, PIPs, MTPs (2nd-5th), thumb IPs, wrists",
      "relevance_score": 2.188326647736484
    }
  ],
  "guideline_citation": "Aletaha D, et al. Arthritis Rheum. 2010;62(9):2569-2581",
  "evidence_trace": [
    {
      "type": "disease_mention",
      "stay_id": "",
      "line_no": "005",
      "snippet": "Diagnostic évoqué : arthrose, pas de PR."
    },
    {
      "type": "disease_mention",
      "stay_id": "",
      "line_no": "005",
      "snippet": "Diagnostic évoqué : arthrose, pas de PR."
    },
    {
      "type": "disease_mention",
      "stay_id": "S0021",
      "line_no": 5,
      "snippet": "Diagnostic évoqué : arthrose, pas de PR."
    },
    {
      "type": "disease_mention",
      "stay_id": null,
      "line_no": "001",
      "snippet": "Antécédents : PR diagnostiquée en 2021, traitée par adalimumab."
    },
    {
      "type": "disease_mention",
      "stay_id": null,
      "line_no": "007",
      "snippet": "Diagnostic : pyélonéphrite. Prise en charge : antibiotiques, arrêt temporaire de l’adalimumab."
    },
    {
      "type": "disease_mention",
      "stay_id": null,
      "line_no": "001",
      "snippet": "Antécédents : PR diagnostiquée en 2021, traitée par adalimumab."
    },
    {
      "type": "disease_mention",
      "stay_id": "S0022",
      "line_no": 1,
      "snippet": "Antécédents : PR diagnostiquée en 2021, traitée par adalimumab."
    },
    {
      "type": "lab",
      "test": "RF",
      "stay_id": "",
      "line_no": "003",
      "snippet": "Laboratoire (J1) : CRP 10 mg/L, VHS 20 mm/h, RF : négatif (8 UI/mL), anti-CCP : négatif (<5 U/mL)."
    },
    {
      "type": "lab",
      "test": "anti-CCP",
      "stay_id": "",
      "line_no": "003",
      "snippet": "Laboratoire (J1) : CRP 10 mg/L, VHS 20 mm/h, RF : négatif (8 UI/mL), anti-CCP : négatif (<5 U/mL)."
    },
    {
      "type": "lab",
      "test": "CRP",
      "stay_id": "",
      "line_no": "003",
      "snippet": "Laboratoire (J1) : CRP 10 mg/L, VHS 20 mm/h, RF : négatif (8 UI/mL), anti-CCP : négatif (<5 U/mL)."
    },
    {
      "type": "lab",
      "test": "VHS",
      "stay_id": "",
      "line_no": "003",
      "snippet": "Laboratoire (J1) : CRP 10 mg/L, VHS 20 mm/h, RF : négatif (8 UI/mL), anti-CCP : négatif (<5 U/mL)."
    },
    {
      "type": "lab",
      "test": "RF",
      "stay_id": null,
      "line_no": "001",
      "snippet": "Antécédents : PR diagnostiquée en 2021, traitée par adalimumab."
    },
    {
      "type": "lab",
      "test": "anti-CCP/ACPA",
      "stay_id": null,
      "line_no": "001",
      "snippet": "Antécédents : PR diagnostiquée en 2021, traitée par adalimumab."
    },
    {
      "type": "lab",
      "test": "CRP",
      "stay_id": null,
      "line_no": "001",
      "snippet": "Antécédents : PR diagnostiquée en 2021, traitée par adalimumab."
    },
    {
      "type": "drug",
      "name": "adalimumab",
      "stay_id": null,
      "line_no": "001",
      "snippet": "Antécédents : PR diagnostiquée en 2021, traitée par adalimumab."
    },
    {
      "type": "drug",
      "name": "ampicilline",
      "stay_id": null,
      "line_no": "005",
      "snippet": "Culture urinaire : E. coli sensible à l’ampicilline."
    },
    {
      "type": "drug",
      "name": "antibiotiques",
      "stay_id": null,
      "line_no": "007",
      "snippet": "Prise en charge : antibiotiques, arrêt temporaire de l’adalimumab."
    }
  ]
}